Lenti-ITGB3 CAR (scFv-CD4ζ, PM6/13)-VP(VP-CAR-LC299)
The ready-to-use lentiviral particles of Lenti-ITGB3 CAR (scFv-CD4ζ, PM6/13)-VP is packaged using 3rd generation of lentiviral packaging system, in which the gene of CAR will be driven by a CMV promotor. The target gene of scFv (PM6/13)-CD4-CD3ζ packaged in lentiviral particles could be used for high efficency tranduction of T cells and stably integrated expression.
Specifications
Type of Therapeutics
Chimeric Antigen Receptor
Expression Cassette
scFv (PM6/13)-CD4-CD3ζ
Packaging System
Lentivirus
Targeting Diseases
Chronic lymphocyticleukemia (CLL)
Target
Introduction
Integrin beta-3 (β3) or CD61 is a protein that in humans is encoded by the ITGB3 gene. CD61 is a cluster of differentiation found on thrombocytes. Defectively expressed β3 integrin subunit has been correlated with presence of endometriosis, and has been suggested as a putative marker of this condition.
Alternative Names
ITGB3; integrin subunit beta 3; GT; CD61; GP3A; BDPLT2; GPIIIa; BDPLT16
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Related Products
| Cat# |
Description |
| CAR-T-3-L339-2XZ |
Anti-ITGB3 scFv h(CD28-OX40-CD3ζ) CART, pCDCAR1 |
| CAR-T-2-L339-4Z |
Anti-ITGB3 scFv h(CD4-CD3ζ) CART, pCDCAR1 |
| CAR-T-1-L339-G |
Anti-ITGB3 scFv h(FcεRIγ) CART, pCDCAR1 |
| VP-CAR-LC300 |
Lenti-ITGB3 CAR (scFv-CD8-CD3ζ, PM6/13) Viral Particle |
| CAR-T-2-L339-2G |
Anti-ITGB3 scFv h(CD28-FcεRIγ) CART, pCDCAR1 |
| VP-CAR-LC293 |
Lenti-ITGB3 CAR (scFv-CD28, PM6/13) Viral Particle |
| VP-CAR-LC303 |
Lenti-ITGB3 CAR (scFv-CD28-41BB-CD3ζ, PM6/13) Viral Particle |
| CAR-T-2-L339-8Z |
Anti-ITGB3 scFv h(CD8-CD3ζ) CART, pCDCAR1 |
| VP-CAR-LC294 |
Lenti-ITGB3 CAR (scFv-FcεRIγ, PM6/13) Viral Particle |
| VP-CAR-LC302 |
Lenti-ITGB3 CAR (scFv-b2c-CD3ζ, PM6/13) Viral Particle |
Leukemia
Kits for CARs/TCRs Development 
Datasheet
Subscribe to Our Newsletter for Updates: